Imide-Based PROTACs for Targeted Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases such as multiple myeloma and cancers face challenges in effectively targeting and modulating certain protein classes, particularly transcription factors, due to non-specific effects and the difficulty in targeting protein-protein interactions.
Innovation Solution
Development of bifunctional compounds, known as proteolysis targeting chimeric (PROTAC) compounds, which recruit endogenous proteins to an E3 Ubiquitin Ligase for degradation, utilizing a cereblon E3 Ubiquitin Ligase binding moiety and a protein targeting moiety to specifically degrade target proteins, thereby modulating their levels and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule drugs are used to target protein-protein interactions, then therapeutic effects can be achieved, but the large contact surfaces and shallow grooves make targeting difficult
Solution Approach 1:
The bifunctional compound is divided into two distinct functional moieties: a first moiety that binds to the target protein and a second moiety that binds to the E3 ubiquitin ligase. This segmentation allows each moiety to independently optimize its binding to its respective target, overcoming the difficulty of targeting large protein-protein interaction surfaces with a single small molecule.
Solution Approach 2:
The E3 ubiquitin ligase acts as an intermediary that bridges the small molecule compound and the target protein. Instead of directly inhibiting the protein-protein interaction, the compound recruits the E3 ligase to the target protein, which then catalyzes ubiquitination and degradation of the target. This intermediary mechanism converts a difficult binding problem into a more manageable recruitment problem.
2Reliability
If E3 ligases are targeted to achieve substrate specificity, then therapeutic specificity is improved, but the field remains underdeveloped due to challenges in ligand development
Solution Approach 1:
The E3 ubiquitin ligase serves multiple functions in this system: it provides substrate specificity through its inherent recognition of target proteins, acts as a catalytic engine for ubiquitination, and serves as a recruitment platform for the bifunctional compound. This multi-functionality leverages the natural capabilities of the E3 ligase to achieve both specificity and therapeutic effect.
Solution Approach 2:
The invention changes the fundamental parameter of ligand design from direct inhibition to recruitment. Instead of designing molecules that directly bind and inhibit protein-protein interfaces, the approach uses molecules that recruit E3 ligases to target proteins, fundamentally altering the binding mode and pharmacological mechanism while simplifying ligand development.
3Stability of the object's composition
If traditional inhibitors are used, then existing therapeutic approaches can be maintained, but they fail to effectively degrade target proteins and lower their levels
Solution Approach 1:
The bifunctional compound performs preliminary action by recruiting the E3 ubiquitin ligase to the target protein before degradation occurs. This pre-positioning of the degradation machinery at the target protein ensures efficient ubiquitination and subsequent proteasomal degradation, effectively lowering target protein levels that traditional inhibitors cannot achieve.
Solution Approach 2:
The invention replaces the mechanical inhibition mechanism (blocking active sites or interfaces) with a biochemical degradation mechanism (ubiquitination followed by proteasomal degradation). This substitution fundamentally changes how target protein levels are controlled, moving from reversible inhibition to irreversible degradation through the cellular protein turnover system.
Data Source
AI summary
The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.